Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Research & Development (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Research & Development for 16 consecutive years, with $66.3 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 9.11% year-over-year to $66.3 million; the TTM value through Mar 2026 reached $260.4 million, up 4.54%, while the annual FY2025 figure was $254.9 million, 3.25% up from the prior year.
  • Research & Development hit $66.3 million in Q1 2026 for Corcept Therapeutics, up from $64.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $70.3 million in Q4 2024 and bottomed at $28.1 million in Q1 2022.
  • Average Research & Development over 5 years is $52.0 million, with a median of $58.5 million recorded in 2024.
  • Year-over-year, Research & Development surged 48.85% in 2023 and then dropped 7.74% in 2025.
  • Corcept Therapeutics' Research & Development stood at $36.8 million in 2022, then soared by 48.85% to $54.7 million in 2023, then rose by 28.5% to $70.3 million in 2024, then decreased by 7.74% to $64.9 million in 2025, then grew by 2.17% to $66.3 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $66.3 million, $64.9 million, and $68.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.